Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Eli Lilly said it plans to invest more than $6 billion in a new facility in Alabama to produce its experimental weight-loss pill.

Large pharmaceutical conglomerate Eli Lilly has announced plans to build a $6 billion manufacturing facility in Huntsville, Alabama. The site will focus on the production of small molecules and ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about ...

Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.

Eli Lilly said on Tuesday it will invest more than $6 billion in a new active drug ingredient manufacturing facility in Huntsville, Alabama, to expand U.S. production and bolster medicine supply ...

Eli Lilly to invest $6 billion in new synthetic medicine facility in Huntsville, AL to boost domestic production and create ...

Eli Lilly plans to start work next year on a facility that will produce orforglipron, officials announced Tuesday in Huntsville.

Eli Lilly just agreed to lower the price of its blockbuster GLP-1 weight loss drug. More than half of the company's revenue comes from just two weight loss drugs. Wall Street may be pricing in too ...